Compare ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraShort Bloomberg Natural Gas ETF vs TG Therapeutics Inc — how do they compare? ProShares UltraShort Bloomberg Natural Gas ETF trades at $24.75 (market cap $141.25M), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 57.8× ProShares UltraShort Bloomberg Natural Gas ETF's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, ProShares UltraShort Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ProShares UltraShort Bloomberg Natural Gas ETF for 10 Days and TG Therapeutics Inc for 16 Days on average.
| KOLD | TGTX | |
|---|---|---|
Market Cap | $141.25M | $8.16B |
Volume | 5,492,367 | 1,735,121 |
Sector | Leveraged / Inverse | Health |
52-Week High | $49.39 | $59.06 |
52-Week Low | $13.58 | $26.94 |
Typical Hold Time | 10 Days | 16 Days |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KOLD is trading at $25.68, up 3.38% today, but faces bearish technical signals with 15 sell indicators versus 2 buy signals. The stock is trading near its pivot point of $25 with immediate resistance at $26 and support at $25. Recent news highlights volatility in natural gas markets with record production levels and geopolitical tensions affecting energy sector sentiment.
The outlook remains cautious with strong bearish momentum indicators and fundamental data gaps. Investment opportunity exists for contrarian traders near support levels, but risks include energy price volatility and production oversupply concerns. Technical weakness suggests potential for further downside testing of $24-$25 support zone.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
